Wegovy vs Mounjaro in Special Populations: A Head-to-Head Comparison

How These Two Drugs Actually Differ

Wegovy and Mounjaro are not interchangeable versions of the same idea. Semaglutide activates only the GLP-1 receptor, slowing gastric emptying and boosting satiety via hypothalamic pathways. Tirzepatide activates both the GIP and the GLP-1 receptor simultaneously. That dual action produces stronger insulin secretion, greater suppression of glucagon, and, in clinical data, consistently larger reductions in body weight and HbA1c.

Mechanism at the receptor level

GIP (glucose-dependent insulinotropic polypeptide) receptors are expressed widely in adipose tissue. When tirzepatide engages them, it may drive greater lipolysis and energy expenditure beyond what GLP-1 activation alone achieves. A 2023 receptor-pharmacology paper in the Journal of Clinical Endocrinology and Metabolism showed that the GIP component of tirzepatide contributes meaningfully to adipose-tissue remodeling independent of the GLP-1 component.

Head-to-head efficacy overview

The SURPASS-2 trial (N=1,879) placed tirzepatide 5 mg, 10 mg, and 15 mg directly against once-weekly semaglutide 1 mg (the diabetes dose, not the 2.4 mg obesity dose) over 40 weeks. At 15 mg, tirzepatide reduced HbA1c by 2.46 percentage points versus 1.86 for semaglutide. Body weight fell by 11.2 kg versus 5.7 kg. SURPASS-2, NEJM 2021.

No published trial has yet randomized patients to semaglutide 2.4 mg versus tirzepatide 10 mg or 15 mg head-to-head in obesity without diabetes. Indirect comparisons from matching-adjusted analyses consistently favor tirzepatide on weight, but direct RCT evidence at full obesity doses is still pending.

Special Population 1: People With Type 2 Diabetes

Both drugs carry FDA approval for glycemic control in type 2 diabetes, but they behave differently in important clinical details. Tirzepatide reaches deeper HbA1c reductions, while semaglutide 1 mg has more long-term cardiovascular data in diabetic populations specifically.

Glycemic efficacy

SURPASS-2 showed tirzepatide 15 mg cut HbA1c by a mean of 2.46% at 40 weeks, putting more patients at goal (<7%) than semaglutide 1 mg. The STEP-2 trial (N=1,210), which used semaglutide 2.4 mg in people with type 2 diabetes, produced a 1.6% HbA1c reduction at 68 weeks alongside 9.6% weight loss. STEP-2, Lancet 2021.

Comparing those numbers cross-trial, tirzepatide appears to have an edge on glycemia. For a patient sitting at HbA1c 9.5% on metformin alone, tirzepatide's deeper reduction may get them to goal without adding a third agent.

Cardiovascular risk in T2D

LEADER (liraglutide), SUSTAIN-6 (semaglutide 0.5/1 mg), and the SELECT trial (semaglutide 2.4 mg, N=17,604) together give GLP-1 agonism a cardiovascular track record spanning nearly 50,000 patient-years. SELECT trial, NEJM 2023. SELECT showed a 20% reduction in major adverse cardiovascular events (MACE) versus placebo in patients with established CV disease and obesity without diabetes.

Tirzepatide's SURPASS-CVOT is expected to report in 2025. Until that data publishes, clinicians managing a diabetic patient after a recent MI have stronger reason to reach for semaglutide.

Insulin combination

For patients already on basal insulin, both drugs can be combined carefully. The SURPASS-3 trial showed tirzepatide superior to titrated insulin degludec on weight and glycemia SURPASS-3, NEJM 2021. Semaglutide combined with basal insulin is also effective, though documented in smaller studies. Either drug requires reducing insulin dose at initiation to avoid hypoglycemia.

Special Population 2: Obesity Without Diabetes

This is the population that most directly compares the full doses of both drugs.

STEP-1 vs SURMOUNT-1

STEP-1 (N=1,961) randomized adults with BMI ≥30 or ≥27 with a comorbidity to semaglutide 2.4 mg or placebo for 68 weeks. Mean body-weight reduction was 14.9% (semaglutide) versus 2.4% (placebo). STEP-1, NEJM 2021.

SURMOUNT-1 (N=2,539) used the same BMI eligibility and ran 72 weeks. Tirzepatide 15 mg produced 20.9% mean weight loss versus 3.1% placebo. SURMOUNT-1, NEJM 2022.

That 6 percentage-point gap translates to roughly 5 to 7 kg of additional weight loss in a 90-kg patient. The populations were not identical, so this cross-trial comparison carries caveats, but the magnitude is large enough that chance alone does not explain it.

Durability after stopping

The STEP-4 extension showed that patients who stopped semaglutide 2.4 mg after 20 weeks regained two-thirds of lost weight within one year. STEP-4, JAMA 2021. Similar rebound data for tirzepatide come from SURMOUNT-4, where participants regained approximately 14% of body weight in the 52 weeks after stopping tirzepatide 10 or 15 mg. Both drugs require long-term or indefinite use to maintain results.

Percent of patients reaching clinically meaningful thresholds

In SURMOUNT-1, 56.8% of patients on tirzepatide 15 mg lost at least 20% of body weight. In STEP-1, 32.0% of semaglutide patients reached that threshold. For a patient with BMI 42 who needs to shed enough weight to become a surgical candidate or reverse fatty liver disease, the probability math favors tirzepatide.

Special Population 3: Polycystic Ovary Syndrome (PCOS)

PCOS affects roughly 8 to 13% of women of reproductive age and involves insulin resistance, hyperandrogenism, and anovulation. Weight loss of even 5% can restore ovulatory cycles in some women. Both agents improve insulin sensitivity, but comparative PCOS-specific trial data remain sparse.

Semaglutide in PCOS

A 2023 RCT (N=84) published in the Journal of Clinical Endocrinology and Metabolism found semaglutide 1 mg weekly reduced body weight by 14.1% and testosterone by 22.3% over 24 weeks in women with PCOS, compared with placebo. Menstrual regularity improved in 72% of participants on semaglutide.

The 2.4 mg dose has not been tested in a dedicated PCOS RCT, but the dose-response relationship from STEP trials makes benefit at the higher dose plausible.

Tirzepatide in PCOS

No published RCT has tested tirzepatide specifically in PCOS as of mid-2025. Case series and observational data show favorable effects on HOMA-IR and androgens, but evidence quality is low. The PCOS Society's 2023 evidence-based guidelines recognize GLP-1 receptor agonists as an emerging option for metabolic management in PCOS but do not yet endorse either agent over the other due to the evidence gap.

For a woman with PCOS who is not attempting pregnancy, either drug is a reasonable choice. For a woman actively trying to conceive, both must be stopped at least two months before conception given teratogenicity concerns, and semaglutide's longer half-life makes the washout timeline more conservative.

Special Population 4: Chronic Kidney Disease

CKD and obesity frequently coexist, and both drugs affect renal endpoints, but their nephroprotective signals differ in strength and evidence grade.

Semaglutide and the kidneys

The FLOW trial (N=3,533) tested semaglutide 1 mg in patients with type 2 diabetes and CKD (eGFR 24 to 75 mL/min/1.73 m2). It was stopped early for benefit: semaglutide reduced the composite kidney endpoint (sustained 40% eGFR decline, dialysis initiation, kidney transplant, or renal death) by 24% versus placebo. FLOW trial, NEJM 2024. The 2.4 mg obesity dose does not yet have a dedicated kidney outcomes trial, but the mechanism and FLOW data support extrapolation.

Tirzepatide and the kidneys

Tirzepatide reduced urine albumin-to-creatinine ratio in post-hoc analyses of SURPASS trials, but a dedicated CKD outcomes trial (SURPASS-KIDNEY) is still enrolling as of 2025. Pharmacokinetic data show no dose adjustment is required for eGFR as low as 15 mL/min/1.73 m2, consistent with the FDA label.

For a patient with CKD stage 3b and type 2 diabetes, semaglutide currently has stronger renal outcome evidence. That clinical picture may change once SURPASS-KIDNEY reports.

Special Population 5: Older Adults (Age 65 and Older)

Older adults face a particular risk calculus: sarcopenic obesity (excess fat with reduced muscle mass) means aggressive weight loss can worsen functional decline if muscle is lost alongside fat.

Weight and muscle in older patients

A pre-specified subgroup analysis of STEP-2 found that adults aged 65 and older on semaglutide 2.4 mg lost proportionally similar total body weight as younger adults, with slightly higher rates of lean mass loss as a fraction of total weight lost. Resistance training concurrent with either drug is strongly recommended by the Endocrine Society's 2023 obesity pharmacotherapy guidelines.

The SURMOUNT-1 subgroup for patients aged 65 and older showed mean weight loss of 16.5% at tirzepatide 15 mg versus 5.0% placebo, with no statistically significant increase in serious adverse events versus younger patients. SURMOUNT-1 supplementary data, NEJM 2022.

Nausea and GI tolerability

Both drugs share nausea, vomiting, and diarrhea as the most common adverse effects. In older adults, GI-related dehydration carries a higher risk of acute kidney injury and orthostatic hypotension. The slower titration schedule for tirzepatide (2.5 mg increments every four weeks) may make dose escalation somewhat more manageable than semaglutide's protocol in frail patients, though no head-to-head tolerability data exist in this subgroup.

Cardiovascular risk reduction in older adults

The SELECT trial enrolled patients aged 45 and older with established CV disease. A pre-specified analysis of the 65-and-older subgroup showed a consistent MACE reduction of roughly 18% with semaglutide 2.4 mg. No equivalent tirzepatide CV outcomes data exist in older adults yet.

Special Population 6: Patients With Heart Failure

Semaglutide in HFpEF

The STEP-HFpEF trial (N=529) tested semaglutide 2.4 mg in patients with heart failure with preserved ejection fraction (HFpEF) and BMI ≥30. At 52 weeks, the Kansas City Cardiomyopathy Questionnaire (KCCQ) clinical summary score improved by 16.6 points with semaglutide versus 8.7 points with placebo. Six-minute walk distance improved by 21.5 meters more than placebo. STEP-HFpEF, NEJM 2023.

Semaglutide 2.4 mg became one of the few agents with a positive symptom-reduction trial in HFpEF. This is a clinically meaningful differentiator.

Tirzepatide in HFpEF

The SUMMIT trial (N=731) tested tirzepatide 15 mg in HFpEF and reported its results in late 2024. Tirzepatide reduced the composite of CV death or worsening heart failure events by 38% versus placebo and improved KCCQ scores by 9.4 points more than placebo. SUMMIT, NEJM 2025 (early release).

Both drugs now have positive HFpEF trial data. Direct comparison is not possible across these trials given different endpoints and populations. For a patient with HFpEF and established coronary artery disease, semaglutide's SELECT MACE data may tip the balance. For a patient whose primary concern is hospitalizations for heart failure, tirzepatide's SUMMIT composite endpoint may carry more weight.

Switching From Wegovy to Mounjaro: Clinical Guidance

Many patients initiated semaglutide first due to availability and are now asking their clinicians about switching. The right answer depends on why they want to switch and what they have already achieved.

Reasons a switch is generally appropriate

A patient who has lost less than 5% body weight after 16 weeks at the maximum tolerated semaglutide dose may benefit from a switch. An HbA1c still above target despite adequate semaglutide titration is another reasonable indication. The Obesity Medicine Association's 2024 position statement notes that switching GLP-1 class agents is acceptable when efficacy is insufficient, provided tolerability is considered.

Reasons a switch may not be necessary

A patient who has lost 15 to 18% body weight on semaglutide 2.4 mg is already in the high-responder range. Adding the GIP mechanism will not guarantee further loss, and switching resets the titration clock, often meaning several weeks at sub-therapeutic doses with renewed nausea risk.

How to switch

Tirzepatide should be started at 2.5 mg regardless of the semaglutide dose the patient was taking. There is no cross-titration table supported by pharmacokinetic data. Because semaglutide 2.4 mg has a half-life of approximately seven days, the last semaglutide injection and the first tirzepatide 2.5 mg injection can be given on the same schedule day. No washout gap is required based on current FDA labeling and published pharmacokinetic data from FDA prescribing information for tirzepatide.

What to expect after switching

Patients often experience a recurrence of nausea during the first two to four weeks of tirzepatide, even if they were GI-tolerant on semaglutide. Incremental weight loss after switching is documented anecdotally and in small observational datasets, but a prospective RCT on switching has not yet been published. Dose escalation to the maximum tolerated tirzepatide dose typically takes 20 weeks following the approved schedule.

Side-Effect Profiles Compared Across Populations

Both drugs share the GLP-1 class side-effect profile: nausea, vomiting, diarrhea, constipation, and injection-site reactions. Differences in frequency and severity are modest in direct-comparison data.

GI adverse events

In SURPASS-2, nausea occurred in 17.6% of tirzepatide 15 mg patients versus 18.0% of semaglutide 1 mg patients. Vomiting was slightly lower with tirzepatide (6.3% vs 8.0%). These rates were similar enough that GI profile should not be the primary differentiating factor in drug selection for most patients.

Pancreatitis and thyroid considerations

Both drugs carry a black-box warning for thyroid C-cell tumors based on rodent data. Neither has been shown to cause medullary thyroid carcinoma in humans at current follow-up durations. Both are contraindicated in patients with a personal or family history of MEN2 or medullary thyroid carcinoma. A history of pancreatitis warrants caution with either agent; neither is absolutely contraindicated in non-acute chronic pancreatitis based on FDA labeling, but specialist consultation is appropriate.

Injection schedule and device

Both drugs use a once-weekly subcutaneous injection. Wegovy comes in a prefilled auto-injector pen with dose-specific pens for each titration step. Mounjaro/Zepbound uses a similar single-use auto-injector. Patients who struggled with the Wegovy device rarely report device problems as a reason to switch; any reported injection issues tend to be technique-based.

Cost and Access Considerations

List pricing for Wegovy is approximately $1,350 per month without insurance. Tirzepatide (Zepbound for obesity) carries a similar list price near $1,060 per month. Both manufacturers offer savings cards for commercially insured patients, but Medicare Part D now covers anti-obesity medications under the Inflation Reduction Act provisions taking effect in 2025. Medicaid coverage varies by state for both agents.

Compounded versions of both drugs circulated widely through 2024. The FDA removed semaglutide from its drug shortage list in October 2024, making compounded semaglutide legally prohibited for most pharmacies. Compounded tirzepatide remains in a contested regulatory space as of mid-2025. FDA shortage database.

Choosing Between the Two: A Decision Framework

The choice between Wegovy and Mounjaro is not a one-size answer. These are the clinical variables that should drive the conversation between patient and prescriber.

Semaglutide 2.4 mg is currently the stronger choice when the patient has:

• Established ASCVD or recent MACE (SELECT trial MACE data)
• CKD with proteinuria (FLOW trial nephroprotection data)
• HFpEF where symptom burden is the primary complaint
• A preference to avoid the GI recurrence that can accompany switching

Tirzepatide 15 mg is currently the stronger choice when the patient has:

• A weight-loss target above 15% of body weight that semaglutide is unlikely to reach
• Type 2 diabetes with HbA1c remaining above 8% on maximally titrated semaglutide 1 mg
• HFpEF where CV death and hospitalization reduction is the primary goal (SUMMIT data)
• Prior inadequate response to semaglutide after full titration and 16 weeks at maximum dose

The Endocrine Society's 2023 obesity pharmacotherapy guidelines state: "The magnitude of weight loss with tirzepatide appears to exceed that achievable with semaglutide, but individual responses vary considerably and both agents are appropriate first-line options." Endocrine Society Clinical Practice Guideline, JCEM 2023.